



UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY
 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

CONFIRMATION NO. 4965

SERIAL NUMBER 09/415,540	FILING DATE 10/08/1999 RULE	CLASS 435	GROUP ART UNIT 1652	ATTORNEY DOCKET NO. PF-0148-3 CPA
------------------------------------	---	---------------------	-------------------------------	---

APPLICANTS
 PHILLIP R. HAWKINS, MOUNTAIN VIEW, CA;
 JENNIFER L. HILLMAN, SAN JOSE, CA;
RECEIVED

AUG 15 2001

TECH CENTER 1600/2900

**** CONTINUING DATA *******
 THIS APPLICATION IS A DIV OF 09/134,593 08/13/1998 PAT 5,981,232
 WHICH IS A DIV OF 08/741,437 10/31/1996 PAT 5,843,665
**** FOREIGN APPLICATIONS *******
IF REQUIRED, FOREIGN FILING LICENSE GRANTED
**** 11/01/1999**

Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	STATE OR COUNTRY CA	SHEETS DRAWING 9	TOTAL CLAIMS 3	INDEPENDENT CLAIMS 1
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged Examiner's Signature _____ Initials _____				


ADDRESS
 Legal Department
 Incyte Pharmaceuticals, Inc.
 3160 Porter Drive
 Palo Alto, CA 94304
BEST AVAILABLE COPY**TITLE**

NOVEL HUMAN PYROPHOSPHATASE

FILING FEE RECEIVED
 760

 FEES: Authority has been given in Paper
 No. _____ to charge/credit DEPOSIT ACCOUNT
 No. _____ for following:

<input type="checkbox"/> All Fees
<input type="checkbox"/> 1.16 Fees (Filing)
<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
<input type="checkbox"/> 1.18 Fees (Issue)
<input type="checkbox"/> Other _____
<input type="checkbox"/> Credit



Receipt

Docket No.: PF-0148-2 DIV

RECEIVED

AUG 15 2001

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

on April 5, 2001

By:

Printed:

Nancy L. (Lynn)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: October 8, 1999

Examiner: Slobodyansky, E.

Group Art Unit: 1652

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

REQUEST FOR A CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the Official Filing Receipt received from the United States Patent and Trademark Office in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:

1. Under the section "Attorney Docket No.," please replace "PF-0148-2 DIV" with --PF-0148-3 CPA--.

Applicants hereby request that the above corrections be entered based on the following enclosed document:

A copy of the CPA Request Transmittal filed via facsimile on January 8, 2001

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. A duplicate of this communication is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 4/5/07

PB
P. Ben Wang

Reg. No. 41,420

Direct Dial Telephone: (650) 621 -7574

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

AUG 15 2001

TECH CENTER 1600/2900

- 2 2001

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
--------------------	-------------	--------------	---------------	-----------------	----------	------------	------------

09/415,540

10/08/1999

1652

760

PF-0148-2-

9

3

1

PF-0148-3 CPA

CONFIRMATION NO. 4965

CORRECTED FILING RECEIPT



OC000000005903338

Legal Department
Incyte Pharmaceuticals, Inc.
3160 Porter Drive
Palo Alto, CA 94304

Date Mailed: 03/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

PHILLIP R. HAWKINS, MOUNTAIN VIEW, CA;
JENNIFER L. HILLMAN, SAN JOSE, CA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A DIV OF 09/134,593 08/13/1998 PAT 5,981,232
WHICH IS A DIV OF 08/741,437 10/31/1996 PAT 5,843,665

Foreign Applications

If Required, Foreign Filing License Granted 11/01/1999

Projected Publication Date: 07/05/2001

Non-Publication Request: No

Early Publication Request: No

Title

NOVEL HUMAN PYROPHOSPHATASE

435

Date: 03/26/2001

RECEIVED

AUG 15 2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

TECH CENTER 1600/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.


NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "**a**," "**an**" and "**the**" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "**new**," "**improved**," "**improvements in**" or "**relating to**" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:




CERTIFICATE OF TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the attention of
Examiner Stokolski, E., Group Art Unit 1652, U.S. Patent and Trademark
Office to Facsimile No. 703-308-4242 on the date shown below.

Phanuz/Sign
Signature

1/8/01
Date

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity) (Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))					
First Named Inventor		Total Pages		Docket No.	
Phillip R. Hawkins		Two (2)		PF-0148-3 CPA	
Address to: Commissioner for Patents Box CPA Washington, D.C. 20231					
This is a request for filing a <input checked="" type="checkbox"/> continuation <input type="checkbox"/> divisional application under 37 CFR 1.53(d), (continued application (CPA)) of prior application number 09/415,540 filed on October 8, 1999 , and entitled: NOVEL HUMAN PYROPHOSPHATASE					
1. <input type="checkbox"/>	Enter the unentered amendment previously filed on _____ Under 37 CFR 1.116 in the prior nonprovisional application.				
2. <input checked="" type="checkbox"/>	A preliminary amendment is enclosed (2 pp.)				
3. <input type="checkbox"/>	This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.53(d), the Commissioner is requested to delete the name(s) of the following person or persons who are named as inventors in the prior nonprovisional application but are not inventors of the invention being claimed in this application:				
4. <input type="checkbox"/>	A new power of attorney is enclosed.				
5. <input type="checkbox"/>	An Information Disclosure Statement (IDS) is enclosed: a. <input checked="" type="checkbox"/> PTO-1449 b. <input checked="" type="checkbox"/> Copies of IDS Citations				
6. <input checked="" type="checkbox"/>	The fee for this application is calculated as follows:				
CLAIMS AS FILED					
Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate	Basic Fee
					\$710.00
Total Claims	5	-20	0	x \$18	\$0
Indep. Claims	1	-3	0	x \$80	\$0
Multiple Dependent Claim(s), if any + \$270					\$
TOTAL FILING FEE					\$ 710.00

7. <input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge Deposit Account No. <u>09-0108</u> in the amount of \$ <u>710.00</u>
8. <input checked="" type="checkbox"/>	<p>The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 09-0108</p> <p><input checked="" type="checkbox"/> fees required under 37 C.F.R. 1.16.</p> <p><input checked="" type="checkbox"/> fees required under 37 C.F.R. 1.17.</p> <p><input checked="" type="checkbox"/> fees required under 37 C.F.R. 1.18</p>
9. <input type="checkbox"/>	Also enclosed:
10. <input checked="" type="checkbox"/>	The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below:
This transmittal is being submitted in duplicate for fee processing.	
<p>Dated: January <u>3</u>, 2001</p> <p style="text-align: right;">  Signature <u>P. Ben Wang, J.D.</u> Typed or printed name <u>41,420</u> Registration Number (if applicable) <input checked="" type="checkbox"/> Inventor(s) <input checked="" type="checkbox"/> Assignee of complete interest <input checked="" type="checkbox"/> Attorney or agent of record </p>	